Anticoagulants Flashcards

1
Q

3 main classes of anti coagulants

A
  1. Anti platelets (aspirin, GpIIb/III a receptor inhibitors etc)
  2. Anti coagulants (Heparin, Warfarin)
  3. Thrombolytics (alteplase, urokinase, streptokinase, anistreplase)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What are important signals in platelet activation

A

Serotonin and ADP

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What affects the release of serotonin and ADP?

A

Prostacyclin from intact endothelial cells –> negative signal to serotonin and ADP secretion –> no platelet activation

Thromboxane A2 from damaged endothelial cells –> positive signal for serotonin and ADP secretion –> platelet activation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

MOA of Aspirin

A

Aspirin is an anti platelet

Inhibits COX irreversibly preventing the conversion of arachidonic acid to prostaglandins and eventually Thromboxane A2 for platelet aggregation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Adverse effects of aspirin

A
  1. Bleeding (inhibits the formation of both PGI2 and TXA2, but TXA2 takes longer to replace. PGI2 inhibits platelet aggregation)
  2. Gastric upset and ulcers - ‘GI bleeding’ as prostacyclins has protective functions in the GI
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Clinical uses of Aspirin

A
  1. Prophylactic treatment of transient cerebral ischaemia
  2. To reduce the incidence of recurrent MI
  3. To decrease mortality in postmyocardial infarction patients
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

GP IIB/IIIA receptor inhibitor examples

A

Abciximab, Tirofiban, Eptifibatide

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

MOA of Gp IIB/IIIA receptor inhibitors

A

Inhibiting GP IIb/IIIa will prevent fibrinogen cross-linking platelets → no clot formation → no fibrin mesh needed to stabilise the platelet aggregation

(GP IIb/IIIa is a platelet membrane protein (receptor) for platelets to receive the fibrin meshes)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Abciximab

A
  • Monoclonal antibody directed against the IIb/IIa complex
  • It reversibly inhibits the binding of fibrinogen and other ligands to gp IIb/IIa
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Tirofiban

A

A small molecular blocker of the gpIIb/IIIa receptor

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Eptifibatide

A

An analog of the sequence at the extreme carbonyl terminal of the delta chain of fibrinogen which mediates the binding of fibrinogen to the receptor

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Clinical uses of Gp IIb/IIIa receptor inhibitors

A

Prevent restenosis after coronary angioplasty

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Clopidogrel & Ticlopidine

A

Anti platelets
ADP receptor blockers → no platelet activation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Dipyridamole

A

Anti platelet
Prevent degradation of cAMP to 5’-AMP → continuous negative signal to prevent serotonin and ADP secretion → no platelet aggregation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Which factors do AT III inactivated

A

inactives thrombin (2a), 9a, 10a by forming stable complexes with them

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

MOA of heparin

A

Allows antithrombin to deactivate the factors better by binding to ATIII and causing a conformational change for more rapid interaction between ATIII and the clotting factor → inactivating clotting factors in the clotting pathway → prevent clotting

17
Q

How does heparin inhibit thrombin?

A

Heparin binds to both 2a and ATIII

18
Q

How does heparin inhibit factor 10a

A

Heparin only needs to bind to ATIII

19
Q

What is Low Molecular Weight Heparin

A

LMWH binds to ATIII and only inactivates factor 10a but not thrombin

20
Q

Clinical use of heparin

A
  1. Treatment of DVT, pulmonary embolism, acute MI (although clot already formed - it helps to prevent further clotting)
  2. Can be used in combination with thrombolytics or Gp IIa/IIIb receptor inhibitors to prevent clotting
  3. Can be used when anticoagulant is needed in pregnancy ***
  4. Given IV or SC (IM administration can cause haematomas)
21
Q

What is the difference between Heparin and Warfarin

A

Heparin can be used in pregnancy

22
Q

Adverse effect of Heparin

A
  1. Haemorrhage:
    - Stop heparin therapy + protamine sulphate (binds to and sequesters heparin)
  2. Thrombocytopenia
23
Q

MOA of Warfarin

A

Warfarin inhibits vitamin K reductase → vitamin K always in the oxidised form → no gamma-carboxylation of factors 2,7,9,10 → no clotting cascade + fibrin mesh formation

24
Q

Clinical uses of warfarin

A

Same as heparin, except contraindicated in pregnancy as it can pass the placenta and cause haemorrhagic disease in the infant

25
Adverse effect of warfarin
1. Bleeding 2. CONTRAINDICATED IN PREGNANCY 3. Drug-drug interaction (metabolised by cyp450 enzyme)
26
Examples of thrombolytics
t-PA (alteplase), urokinase, streptokinase, anistreplase
27
MOA of alteplase
Tissue plasminogen activator → converts plasminogen to plasmin → plasmin breaks down insoluble fibrin mesh to fibrin degradation products
28
Clinical uses of thrombolytics
1. Emergency treatment of coronary artery thrombosis 2. Peripheral arterial thrombosis and emboli 3. Ischaemic stroke (narrow therapeutic window <4.5hr) 4. Intracoronary injection, IV injection
29
Adverse effects of thrombolytics
1. Bleeding 2. Contraindicated in pregnancy + healing wounds
30
When are thrombolytics contraindicated in?
- pregnancy - Healing wounds
31
mode of action of unfractionated hepatin, and the difference from low molecular weight heparin
1. binds and activates plasma protease inhibitor antithrombin III → conformational change → exposes its active site --> forms more inactive complexes with coagulation factor IIa, IXa & Xa by 1000 folds 2. stimulates tissue factor pathway inhibitor (TFPI) release from endothelium to prevent activation of coagulation factor Xa it has a longer polysaccharide side chain that can envelope thrombin, therefore giving enhanced anti Xa and IIa activity